Plain-English translation of NCT02047474 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial studied a combination chemotherapy called mFOLFIRINOX in patients with pancreatic cancer that had not spread and could be removed with surgery. Participants received this four-drug combination before surgery to try to shrink the tumor, then had surgery, and then received more of the same medication afterward. The goal was to see if this approach helped patients live longer and prevented cancer from returning.
Pancreatic cancer is a serious disease, and even when it can be surgically removed, cancer often returns. Researchers wanted to test whether giving this medication before and after surgery could improve survival and reduce the chance of the cancer coming back.
Participants received the four-drug chemotherapy combination as an intravenous infusion every two weeks for six cycles (about 12 weeks total) before surgery. After completing this pre-surgery treatment, they underwent surgery to remove the cancer, and then began another round of six cycles of the same medication within 12 weeks after surgery. The entire treatment course spanned several months and involved regular clinic visits for chemotherapy infusions and monitoring.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States